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Summary:Thyroid dysfunction complicates the metabolic derangement observed in Diabetes Mellitus (DM). It is 
necessary to recognize and treat it when present in order to achieve stability of metabolic control in these patients. The 
prevalence of thyroid dysfunction in type-2 diabetics in our environment is not known. This study was therefore designed 
to determine the prevalence of thyroid dysfunction in Type 2 diabetics seen at the Metabolic Research Unit of University 
College Hospital, Ibadan, Nigeria. Serum TSH, Free T3 & Free T4 assays were performed using Automated Enzyme 
Immunoassay platform on fresh sera from volunteers comprising 64 adult type 2 diabetics and 36, age matched, non 
diabetic controls; weight, height and blood pressures were measured in all subjects. In addition, past lipid profile results of 
type 2 diabetics were retrieved from medical records. Thyroid dysfunction was present in 19 (29.7%) of 64 type 2 diabetics 
and 1 (2.8%) of 36 non diabetic controls (P< 0.05).  The prevalence of thyroid dysfunction is 32.4% in females and 25.9% 
in males.  Secondary hypothyroidism was seen in 78.9%, sub-clinical hypothyroidism in 15.8%, and sub-clinical 
hyperthyroidism 5.2% of subjects with thyroid dysfunction. Abnormal lipid profiles were seen in 35.4% of euthyroid type 
2 diabetics and 100% of hypothyroid type 2 diabetics (P<0.05). 87.5% of type 2 diabetics and 38.8% of controls were 
hypertensive (P<0.05). 7.8% of type 2 diabetics and 50% of controls were obese (P<0.05). The prevalence of thyroid 
dysfunction in type 2 is higher in type 2 diabetics than in controls.  More of Type 2 diabetics were obese and more of them 
were hypertensive compared to controls.  The approach of using TSH first in screening for thyroid dysfunction is not 
sufficient in type 2 diabetics. Routine screening for thyroid dysfunction should be carried out in type 2 diabetics. 
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Thyroid dysfunction is a spectrum of disorders of the 
thyroid gland which manifests either as hyper - or 
hypothyroidism and is reflected in the circulating 
levels of thyroid stimulating hormone (TSH) 
(Tunbridge et al, 1977).  
 Thyroid hormones, namely Tri-iodothyronine 
(T3) and Thyroxine (T4); either or both of which may 
be elevated or reduced have both direct and indirect 
effects on blood glucose homeostasis (Udiong et al., 
2007). Elevated levels of free circulating thyroid 
hormones (hyperthyroidism) produce hyperglycaemia 
by causing polyphagia, enhancing glucose absorption 
from the gastro-intestinal tract, accelerating insulin 
degradation and stimulating glycogenolysis (Loeb, 
1996). Reduced levels of the hormones 
(hypothyroidism) may cause hypoglycaemia (Loeb, 
1996; Cooper, 2003). 
 The prevalence of thyroid dysfunction is higher 
in diabetics than in controls. This has been estimated 
to be between 10 to 15% in diabetes compared to 6% 
in the non-diabetic population (Wu, 2000; Johnson, 
2006; Udiong et al, 2007). Numerous studies reported 
and justified this finding in type 1 diabetics (Cardoso 
et al., 1995; Wu, 2000; Sherman and Gagel, 2005; 
Johnson et al., 2006) and only two studies reported 
the same finding in type 2 diabetics (Perros et al., 
1995; Radaideh et al, 2004).
 
 Although autoimmunity, in which circulating 
antibodies exist to numerous body tissue components 
destroy such tissues was stated to be the underlying 
mechanism behind the increased prevalence of 
thyroid disorders in type 1A diabetes (Hawa et al, 
2006), despite the fact autoimmune thyroid diseases 
are known to be highly prevalent in all forms of 
diabetes; no specific reason has been adduced for an 
increased prevalence of thyroid disorders in antibody 
negative (type 1B) or type 2 diabetics (Wu, 2000; 
Radaideh et al, 2004). However, insulin; the hormone 
required for transporting glucose from plasma across 
cell membranes into the cytosol of many cells 
(including those of the skeletal muscle) is absolutely 
deficient in type 1 diabetics and relatively deficient in 
type 2 diabetics. Some authors have postulated that 
insulin treatment in type 1 diabetics and insulin 
resistance with resultant high plasma insulin levels in 
type 2 diabetes may equally predispose both groups 
to deranged thyroid function (Radaideh et al, 2004; 
Udiong et al 2007; Pasupathi et al, 2008).
 
 Type 2 diabetes is reported in association with 
hypothyroidism in the rare Crow-Fucase syndrome 
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(also called POEMS syndrome). This syndrome 
consists of polyneuropathy, organomegaly, 
endocrinopathies (which includes thyroid 
dysfunction), multiple myeloma and skin changes. 
One-third of patients with POEMS syndrome have 
type 2 diabetes mellitus (Mullai  et al 2001). Type 2 
diabetes accounts for > 90% of diabetes burden all 
over the world (ADA, 2007) despite the fact that it is 
grossly underdiagnosed(Sobnigwi  et al, 2002). 
Because of the insidious nature of type2 DM, it often 
remains undiagnosed until late into the disease when 
complications have set in (Sobnigwi et al, 2002; 
Alvin  et al, 2005; ADA, 2007). The prevalence of 
type 2 DM is rising faster than any other form of 
diabetes because of  increased urbanization which 
encourages development of obesity due to reduced 
physical activity, increased consumption of refined 
foods and snacks globally (Zimmet, 1999; Zimmet  et 
al, 2001).  
 Hypothyroidism, the most commonly diagnosed 
thyroid dysfunction in all studies conducted so far; 
has greater implications for type 2 diabetics in whom 
there is pre-existing dyslipidaemia and the risk of 
cardiovascular disease is increased (Cooper, 2003; 
Rama  et al, 2003; Johnson, 2006). The only available 
studies of thyroid dysfunction in type 2 diabetics are 
from Portugal and Jordan (Perros et al, 1995; 
Radaideh et al, 2004). The study by Cardoso et al, 
(1995) was on type 1 diabetic Nigerians in Lagos 
while Udiong et al (2007) studied a mixed population 
of diabetic Nigerians in Calabar. There is the need to 
know the prevalence, the pattern and the effects of 
thyroid dysfunction in a purely type 2 diabetic 
population in Nigeria. The prevalence of thyroid 
dysfunction in type-2 diabetics in Nigera is not 
known. This study was therefore designed to 
determine the prevalence of Thyroid Dysfunction in 
Type 2 Diabetics seen at the Metabolic Research Unit 
of University College Hospital, Ibadan, Nigeria. 
 
MATERIALS AND METHODS 
 
This study was carried out at the Metabolic Research 
Unit of the University College Hospital, Ibadan, 
Nigeria between August 2008 and February 2009. 
Study subjects include 64 adult, known type 2 
diabetic patients and 36 non diabetic controls of 
similar ages without evidence of thyroid disease, who 
gave voluntary informed consent to participate in the 
study. Questionnaires were administered to record 
findings on general physical examination, past 
medical, drug and family histories of volunteers. In 
addition, Type 2 Diabetics had their hospital files 
reviewed to verify their ages at diagnosis, their past 
lipid profile results, the adequacy of their glycaemic 
controls, the presence of complications and the 
medications they take.  Type 2 diabetics diagnosed at 
ages below 30 years or those suffering from other 
acute illnesses/starvation/stress, those with previous 
evidence of thyroid disease or treatment for same, 
those on drugs known to affect thyroid function and 
pregnant women were excluded.  
Diabetes Mellitus (DM) was ruled out in controls 
using Fasting Plasma Glucose (FPG). Those with 
FPG < 6.0mmol/L were accepted as controls if they 
are not on any hypoglycaemic medication. Ethical 
approval for this study was obtained from the joint 
Health Research Ethical Committee of the University 
of Ibadan and University College Hospital, Ibadan 
(UI/UCH-HREC). 
 Venous blood samples of participants were 
collected into plain serum bottles, allowed to clot and 
the serum was separated by centrifugation within 3 
hours of collection. These sera were kept frozen at -
20
o
C until analysis. Frozen sera from the 64 Type 2 
Diabetics and 36 controls were thawed and assayed 
for TSH, FT3 and FT4 in three runs, each on a 
different day using an automated immunoassay 
platform (AIA-600II) by TOSOH BioScience Inc. 
Japan.   
 Control samples provided in the reagent packs 
were analysed daily with each run of these analytes 
according to manufacturer’s instruction. Co-efficient 
of Variations (C.V) for TSH, FT3 and FT4 are 
presented in table 1.  The reference ranges for the 
analytes measured are presented in table 2. TSH and 
FT4 assays were performed before and after spiking 
three serum samples with three different levels of 
both analytes, recovery values ranged between 96.7% 
and 109.4% for all assays. The above procedure was 
repeated with serial dilutions of serum samples 
containing high concentrations of TSH and FT4, 
recovery values ranged between 98.3% and 101.3%.  
TSH below 0.38mU/L is regarded as low and TSH 
above 4.31mU/L is regarded high. Similarly, FT3 
below 3.2pmol/L or above 5.9pmol/L are regarded 
low and high respectively and FT4 below 10.6pmol/L 
and above 21.0pmol/L are regarded low and high 
respectively.  An elevated TSH is interpreted as 
hypothyroidism, in this condition, if FT4 is low it is 
overt hypothyroidism, if FT4 is normal it is referred 
to as mild (subclinical) hypothyroidism, if FT4 is 
high it is secondary hyperthyroidism or thyroid 
hormone resistance. A low FT4 which in this setting 
is not artefactual, when seen in association with a low 
or normal TSH is regarded as secondary 
hypothyroidism whether FT3 is low or not.  When 
TSH is low, it is regarded as overt hyperthyroidism 
which may be primary if FT4 is high, mild 
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hyperthyroidism if FT4 is normal and secondary 
hypothyroidism if FT4 is low (table 3).    
 The glycaemic control was assessed by the average 
values of their fasting and 2 hour post prandial 
glucose (2HPPG) levels in the 6 months preceding 
this study which is available for all of them (glycated 
haemoglobin was not readily available). The 
Glycaemic Control (GC) was graded as “good” if 
average FPG in the past six months is ≤ 
7.2mmol/l(130mg/dl) and 2HPPG is ≤ 10.0mmol/l 
(180mg/dl), and “poor” if either FPG average is 
>7.2mmol/l or 2HPPG average is >10.0mmol/l. 
 Body Mass Indices (BMIs) were calculated from 
their weights measured in kilograms (kg) and heights 
in metres (m) using the standard formular. Subjects 
were classified “normal weight” if BMI is <25 or 
“abnormal weight” (Overweight/Obese) if BMI is 25 
or higher. Blood Pressure (BP), measured with a 
manual sphygmomanometer was taken on two 
occasions; and the average of two readings (each 
taken on a different day at least a week apart after 
initial evaluation) following standard procedure was 
recorded. Normal BP was defined as a Systolic BP < 
140mmHg and/or Diastolic BP < 90mmHg in an 
adult who is not on treatment for hypertension. 
Subjects who fail to satisfy these criteria were 
considered to have a high BP (Table 4).  
 Lipid profile results were categorised as either 
Normal or Dyslipidaemic according to the World 
Health Organisation (WHO) risk categorisation of 
plasma lipid values. Those with Total Cholesterol 
and/or Low Density Lipoprotein (LDL-) Cholesterol 
and/or triglyceride above the optimal level, or High 
Density Lipoprotein (HDL-) Cholesterol below the 
optimal level for individuals at risk of developing 
cardiovascular disease were classified 
“dyslipidaemic”. 
 Statistical Analysis was done using SPSS Version 
13 for windows. The differences observed between 
cases and controls with regards to qualitative 
variables (sex, lipid profile, and glycaemic control) 
were assessed using Pearson’s Chi-Square test while 
the differences observed in the two groups with 
regards to quantitative variables (age and BMI) were 
tested for significance using Student’s t-test. 





The general clinical characteristics and demographic 
features of the study population (n═100) are 
presented in Table 4.  Sixty-four patients (27 males 
and 37 females) are type 2 diabetics who are the 
study subjects and the remaining 36 are the control 
subjects. The mean ages ± (2SD) of study subjects 
and controls are 50.1±18.9years (range 32-66years) 
and 53.8±24years (range 30-70years) respectively. 
Thyroid dysfunction was found in 29.7% out of type 
2 DM patients, and in 2.8% of controls (P═0.002).  
 
Table 1. Precision profile for TSH, FT3   FT4 assays. 




TSH A 2.9% 5.0% 
 B 2.3% 4.8% 
 C 2.5% 4.4% 
FT3 A 4.7%                            6.9%
 B 3.9%                            4.8%
 C 2.4%                            3.6%
FT4 A 3.3%                            4.9%
 B 2.7%                            3.5%
 C 1.8%                            2.4%
C.V=Coefficient of Variation 
 
Table 2. 
Reference values for TSH, FT3 & FT4 using AIA-600II 
(TOSOH) 
ANALYTE             REFERENCE RANGE 
TSH (mU/L)                         0.38-4.32 
FT3 (pmol/L)                        3.2-5.9 
FT4 (pmol/L)                       10.6-21.0 
TSH ═ Thyroid Stimulating Hormone, FT3 ═ Free Tri-
iodothyronine, FT4 ═ Free Thyroxine 
 
 Those with thyroid dysfunction consists of 
12(32.4%) out of 37 diabetic females and 7(25.9%) 
out of 27 diabetic males. This puts the overall 
prevalence of thyroid dysfunction in type 2 diabetics 
at 32.4% and 25.9% in females and males 
respectively (Tables 5).  
 
Table 3.Criteria for diagnosis of thyroid dysfunction in this study 
  TSH                       FT4                         FT3                          Diagnosis 
                                                                                                    Euthyroid 
                                                                                                    SCl. Hypothyroidism 
          
                                                                                                    SCl. Hyperthyroidism 
 
                                                                                                    20 hypothyroidism                                                  
 
SCl = sub clinical,  2
0  
= secondary,   ═ High,             ═ Normal,  ═ Low 
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The pattern of thyroid dysfunction observed in the 
Type 2 DM Patients and the controls is presented in 
table 3. Fifteen (78.9%), out of 19 study subjects with 
thyroid dysfunction have secondary hypothyroidism 
and these include 10 females and 5 males whose TSH 
values were within the stipulated reference range and 
FT3 & FT4 were both low (table 4), three (15.8%) of 
them have mild (sub-clinical) hypothyroidism with 
high TSH while both FT3 & FT4 were normal. One 
person (5.2%) has subclinical hyperthyroidism (table 
5).  Seven (25.9%) of twenty seven type 2 diabetic 
males, and twelve (33.6%) of thirty seven female 
type 2 diabetics have thyroid dysfunction (table 5). 
Fifty (71.8%) of sixty four type 2 diabetics and 
eighteen (50%) of thirty six controls were either 
overweight or obese (P ═ 0.004), while 87.5% of type 
2 diabetics versus 38.8% of controls were 
hypertensive (P=0.000).  
 Lipid profile results were available for 43 out of 
64 study subjects, these include 31 out of the 45 
euthyroid type 2 diabetics and 12 out of the 19 type 2 
diabetics with thyroid dysfunction (see table 6). 
Eleven (35.48%) of the 31 results of the euthyroid 
type 2 diabetics show dyslipidaemia as against their 
twelve (100%) hypothyroid counterparts (P ═ 0.001). 
Lipid profile result was not available for the single 
patient with subclinical hyperthyroidism (Table 6).  
 The mean age and BMI across diagnostic groups 
in type 2 diabetics were presented in table 3. There is 
no significant age and BMI difference between the 
thyroid type 2 diabetics and those with thyroid 
dysfunction. The only control subject with thyroid 
dysfunction (subclinical hyperthyroidism) is a 
43year-old, normotensive female with a normal 
weight. 
Table 4. 
Demographic and Physical Characteristics of the Study 
Population. 
Characteristics   Diabetics Controls 
Sex: male   27 13 
female 37 23 
mean age (years) 50.06                                          53.78
BMI normal 14                                               18
obese 50                                               18
BP:                                                                                                                                     normal 8 22
 high                                           56                             14
Diagnosis      Eu 45                                              35
 Dys 19                                               1
BP ═ Blood Pressure,  BMI ═ Body Mass Index,   
Eu ═ Euthyroid,  Dys ═. Thyroid Dysfunction 
 
Table 5. 
Thyroid function pattern in Type 2 Diabetics and Controls 
Thy. function   Diabetics Controls Total 
Euthyroid male   20                                      15                   35 
female 25                                      20                    45 
Total 45(70.3%)                       35((97.2%)                          80 
2
0
 Hypo male   5                                     ------                          5
female 10                                  --------                              10 
Total 15(23.4%)                       ---------                               15
SCl. 
Hypo 
male   1                                    ----------                              1
female 2                                    -----------                              2
Total 3(4.7%)                           ------------                            3
SCl. 
Hyper 
male   1                                     -----------                              1
female –                                        1                      1 
Total 1(1.6%)                           I(2.8%)                               2
Grand 
total 
 64(100%)                                     36(100%)             100
20 Hypo.═ Secondary Hypothyroidism, SCl. Hypo  ═  Subclinical 
Hypothyroidism, SCl. Hyper ═ Subclinical Hyperthyroidism.
 
TABLE 6.  
Qualitative Variables and Thyroid Function in Type 2 Diabetics 
Variable  Eu 2
0
 Hypo SCl. Hypo SCl. Hyper 
LP : Total 35 9 3 -- 
 Dyslip 11 (35.5%) 9 (100%) 3(100%) -- 
GC: Total 45 15 3 1 
 Poor 18(40%) 11(63.6%) 2(66.7%) 1(100%) 
Sex: Male 20 5 1 1 
 Female 25 10 2 -- 
BMI: Total 45 15 3 1 
 >25 37 10 1 1 
Age (yr): Total 45 15 3 1 
 ≥50 37 15 2 1 
L.P ═ Lipid Profile, G.C ═ Glycaemic Control, OHA ═ Oral Hypoglycaemic Agents, Dyslip ═ Dyslipidaemia, Insul.═ Insulin.Eu ═ 





Thyroid dysfunction is known to be more prevalent in 
type 1 diabetics compared to the general non diabetic 
populations. The prevalence of thyroid dysfunction 
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had also been reported to be higher in type 2 diabetics 
in Jordan and in the United Kingdom but it is still not 
clear which event precedes which. This is so because 
type 2 diabetics are not routinely screened for thyroid 
dysfunction upon diagnosis. The hyperglycaemia 
seen in diabetics is known to have negative effects on 
thyroid function precisely blunting the pituitary TSH 
response to stimulation by hypothalamic TRH. This 
may be due to possible alteration of post translational 
glycosylation of TRH thus affecting the biological 
activity. This mechanism suggests that diabetes may 
predispose to thyroid dysfunction. 
However, both hypothyroidism and hyperthyroidism 
are known to have adverse effects on glycaemic 
control in diabetics with hyperthyroidism on its own 
resulting in diabetes. This study entails screening for 
biochemical evidence of thyroid disease in a purely 
type 2 diabetic Nigerian population who did not have 
symptoms or signs of thyroid dysfunction; and an 
identical population of non-diabetics. This is in view 
of the widely reported effects of the various forms of 
thyroid dysfunction on blood glucose homeostasis. 
The findings in this study include; an overall thyroid 
dysfunction prevalence significantly higher (p<0.05) 
in type 2 diabetics than in controls. This finding 
agrees with those of Radaideh et al (2004) and 
Smithson (1998) both of whom reported similar 
findings in Jordan and in the UK respectively. 
However the prevalence rate of 29.7% found in type 
2 diabetics in this study is much higher than 10.8% 
reported by Smithson (1998) in the UK and 12.5% 
reported by Radaideh et al (2004) in Jordan.  
The notable differences in prevalence observed in 
these studies may be explained by the (1) racial, sex 
and age differences between the populations studied 
and (2) methodological differences between this 
study and the other studies. Racial factors are 
recognized causes of variation in epidemiology of 
diseases. While this study was carried out on 
Nigerian subjects, Radaideh et al (2004) studied 
Arabian subjects in Jordan and The Smithson (1998) 
studied British subjects in the UK. TSH, FT3 & FT4 
were assayed on an Automated Immunoassay 
Analyser (AIA) format while the Jordanian study 
used a manual technique based on ELISA principle. 
Modern AIAs have better analytical performance 
characteristics compared to manual methods.  
The finding of a sex related prevalence rate of 32.4% 
in female and 25.9% in male type 2 diabetics in this 
study also agrees with the previous works of 
Tunbridge et al (1977), Udiong et al (2007), Wu 
(2000), Johnson (2006) and Rama (2003) who 
reported higher prevalence of thyroid dysfunction in 
females than in males not only in diabetics but also in 
the non-diabetic population. None of these studies 
gave reasons other than age because the prevalence of 
both disorders i.e. thyroid dysfunctions and type 2 
diabetics increase with age.      
Hypothyroidism found in 18 out of 19 Type 2 
Diabetics with thyroid dysfunction in this study is 
also in agreement with all previous studies cited 
above including the Wickham survey(Tunbridge  et 
al, 1977) and the Colorado study (Sobnigwi  et al, 
2002) which reported hypothyroidism as the most 
prevalent form of thyroid dysfunction observed in all 
the studies.  
However, the finding of secondary hypothyroidism in 
the majority (78.9%), of those with thyroid 
dysfunction with subclincal hypothyroidism 
constituting only 15% of cases in this study; coming 
only next to secondary hypothyroidism in prevalence, 
is in sharp contrast with the earlier studies of Cooper 
(2003), Johnson (2006), Radaideh  et al (2004), Rama  
et al (2003), Weetman (1997), all of which reported 
subclinical hypothyroidism as the most prevalent 
thyroid dysfunction. Of all these, only Radaideh  et al 
(2004) studied purely type 2 diabetic patients who are 
of Arab extraction.  
 Although secondary hypothyroidism is believed to 
be very rare in the general population, there is no 
report on its prevalence in a special population like 
type 2 diabetics. Age 50 years or above, female sex, 
pituitary disease, surgery or irradiation and Sheehan’s 
syndrome are some of the predisposing factors to 
secondary hypothyroidism. Hypothalamic TRH 
deficiency (tertiary-hypothyroidism) is a differential 
diagnosis which may be discountenanced in this 
situation because hyperglycaemia itself is known to 
induce a low T3 state and absence of TSH response 
to TRH. Chronic hyperglycaemia in these patients via 
the above mechanism results in atrophy of the thyroid 
gland. Most (66.7%) of these patients are females 
above 50 years of age and suffer from chronic 
hyperglycaemia as a result of poor glycaemic control. 
One of them is a 56year old woman with Sheehan’s 
syndrome diagnosed about 20 years ago. For these 
reasons, trying a TRH stimulation of TSH to 
distinguish a secondary from a tertiary 
hypothyroidism may not be worthwhile.  
 The single hyperthyroid TSH 2.8 mU/l, FT4 24.5 
pmol/l and FT3 3.6pmol/l) type 2 diabetics in this 
study is a male and this agrees with Udiong  et al, 
(2007) who reported a higher prevalence of 
hyperthyroidism in male diabetics in Calabar. 
Dyslipidaemia is present in 100% of hypothyroid 
type 2 diabetics with lipid profile results as compared 
to 35.48% of their euthyroid counterparts (P=0.001) 
This finding agrees with that of and Rama et al 
(2003) who found a significant association between 
hypothyroidism and dyslipidaemia in Hyderabad, but 
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differs from Nobre et al, (2002) who found no 
difference between hypothyroid and euthyroid type 2 
diabetics in Portugal. Type 2 DM on its own is 
associated with atherogenic dyslipidaemia the way 
hypothyroidism also is; that may explain the finding 
of dyslipidaemia in 100% of hypothyroid 
dyslipidaemia in this study. Apart from this, type 2 
diabetes is found in association with atherogenic 
dyslipidaemia, central obesity and hypertension in the 
insulin resistance syndrome (Metabolic Syndrome). 
More than 25% of type 2 diabetics in the US have 
this syndrome (Zimmet et al, 2001). 
Type 2 diabetics in this study are not significantly 
heavier than non diabetic controls (P>0.05); this is 
contrary to the findings of Zimmet  et al (2001) who 
reported an increased prevalence of overweight and 
obesity in type 2 diabetics. However, the average 
blood pressure which is significantly higher than that 
of controls (P<0.05) in this study agrees with Zimmet 
et al (2001) and many other studies which reported an 
increased prevalence of hypertension in type 2 
diabetics. 
The index of glycaemic control used in this study is 
plasma glucose average in the last 6 months 
preceding this assay, only one of those with good 
glycaemic control and 2 of those with poor glycaemic 
control had an HbA1c result to confirm the FPG-
average based categorization as “good” or “poor” 
control. Forty percent of euthyroid, 63.6% of 
secondary hypothyroid, 66.7% of of subclinical 
hypothyroid and 100% of subclinical hyperthyroid 
type 2 diabetics in this study respectively show poor 
glycaemic control (P>0.05). This shows, contrary to 
the view of some authors; that glycaemic control may 
not be influenced by thyroid function status in this 
study. No significant association was found between 
medications used and thyroid function status in type 2 
diabetics in this study. The limitation here is that 
many other (confounding) variables, notably 
treatment compliance which influence glycaemic 
control cannot be monitored.  
In summary, the prevalence of thyroid dysfunction is 
higher in Type 2 DM (as it is in Type 1 DM) than that 
in the general population, more females are affected 
than are males. Secondary hypothyroidism is the 
commonest thyroid dysfunction in type 2 diabetics 
here in Ibadan. Dyslipidaemia is almost always 
present in hypothyroid type 2 diabetics. Routine 
screening and regular monitoring of type 2 Diabetics 
for thyroid dysfunction is warranted. The TSH- first 
approach to screening for thyroid dysfunction is not 
adequate for type 2 diabetics. There is the need to 
determine method specific reference intervals for 
local application to allow an unbiased interpretation 
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